Your browser doesn't support javascript.
loading
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Abou Dalle, Iman; Kantarjian, Hagop M; Ravandi, Farhad; Daver, Naval; Wang, Xuemei; Jabbour, Elias; Estrov, Zeev; DiNardo, Courtney D; Pemmaraju, Naveen; Ferrajoli, Alessandra; Jain, Nitin; Wang, Sa A; Jammal, Nadya; Borthakur, Gautam; Naqvi, Kiran; Pelletier, Sarah; Pierce, Sherry; Andreeff, Michael; Garcia-Manero, Guillermo; Cortes, Jorge E; Kadia, Tapan M.
Afiliação
  • Abou Dalle I; Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang X; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour E; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jammal N; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Borthakur G; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Naqvi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pelletier S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Georgia Cancer Center, Augusta, Georgia.
Cancer ; 127(11): 1894-1900, 2021 06 01.
Article em En | MEDLINE | ID: mdl-33449377
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Inibidores da Angiogênese / Quimioterapia de Manutenção / Lenalidomida Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Líbano País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Inibidores da Angiogênese / Quimioterapia de Manutenção / Lenalidomida Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Líbano País de publicação: Estados Unidos